Evolutionary Origin of Human PALB2 Germline Pathogenic Variants

Int J Mol Sci. 2023 Jul 12;24(14):11343. doi: 10.3390/ijms241411343.

Abstract

PALB2 (Partner and localizer of BRCA2) is crucial for repairing DNA double-stranded breaks (DSBs) through homologous recombination (HR). Germline pathogenic variation in PALB2 disrupts DNA damage repair and increases the risk of Fanconi Anemia, breast cancer, and ovarian cancer. Determination of the evolutionary origin of human PALB2 variants will promote a deeper understanding of the biological basis of PALB2 germline variation and its roles in human diseases. We tested the evolution origin for 1444 human PALB2 germline variants, including 484 pathogenic and 960 benign variants. We performed a phylogenic analysis by tracing the variants in 100 vertebrates. However, we found no evidence to show that cross-species conservation was the origin of PALB2 germline pathogenic variants, but it is indeed a rich source for PALB2 germline benign variants. We performed a paleoanthropological analysis by tracing the variants in over 5000 ancient humans. We identified 50 pathogenic in 71 ancient humans dated from 32,895 to 689 before the present, of which 90.1% were dated within the recent 10,000 years. PALB2 benign variants were also highly shared with ancient humans. Data from our study reveal that human PALB2 pathogenic variants mostly arose in recent human history.

Keywords: PALB2; evolutionary origin; paleoanthropology; phylogenetic.

MeSH terms

  • Animals
  • BRCA2 Protein / genetics
  • Breast Neoplasms* / pathology
  • DNA Repair
  • Evolution, Molecular
  • Fanconi Anemia Complementation Group N Protein* / genetics
  • Fanconi Anemia* / genetics
  • Female
  • Genetic Predisposition to Disease
  • Germ Cells / metabolism
  • Germ-Line Mutation*
  • Humans
  • Ovarian Neoplasms* / genetics

Substances

  • BRCA2 Protein
  • Fanconi Anemia Complementation Group N Protein
  • PALB2 protein, human

Grants and funding

This work was supported by grants from the Macau Science and Technology Development Fund (085/2017/A2, 0077/2019/AMJ, 0032/2022/A1), the University of Macau (SRG2017-00097-FHS, MYRG2019-00018-FHS, 2020-00094-FHS), the Faculty of Health Sciences, University of Macau (FHSIG/SW/0007/2020P, MOE Frontiers Science Center for Precision Oncology pilot grant, and a startup fund) to S.M.W.